[
    [
        {
            "time": "",
            "original_text": "五粮液、恒瑞医药、智飞生物、药明康德、中联重科、金龙鱼等均下挫逾7%",
            "features": {
                "keywords": [
                    "五粮液",
                    "恒瑞医药",
                    "智飞生物",
                    "药明康德",
                    "中联重科",
                    "金龙鱼",
                    "下挫"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "白酒",
                    "医药",
                    "生物科技",
                    "机械制造",
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "五粮液、恒瑞医药、智飞生物、药明康德、中联重科、金龙鱼等均下挫逾7%",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药周报：坚守具备估值安全垫、业绩增长确定性高的二线龙头",
            "features": {
                "keywords": [
                    "医药",
                    "估值安全垫",
                    "业绩增长",
                    "二线龙头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药周报：坚守具备估值安全垫、业绩增长确定性高的二线龙头",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "东吴证券 - 医药生物行业跟踪周报：医药板块估值有多贵？哪些估值贵【行业研究】",
            "features": {
                "keywords": [
                    "东吴证券",
                    "医药生物",
                    "估值",
                    "行业研究"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东吴证券 - 医药生物行业跟踪周报：医药板块估值有多贵？哪些估值贵【行业研究】",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "平安证券 - 生物医药行业周报：《政府工作报告》发布，将进一步深化医药卫生体制改革【行业研究】",
            "features": {
                "keywords": [
                    "平安证券",
                    "生物医药",
                    "政府工作报告",
                    "医改",
                    "政策"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "平安证券 - 生物医药行业周报：《政府工作报告》发布，将进一步深化医药卫生体制改革【行业研究】",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "牧原股份、智飞生物、万华化学、海尔智家、邮储银行等明星股涨超4%",
            "features": {
                "keywords": [
                    "牧原股份",
                    "智飞生物",
                    "万华化学",
                    "海尔智家",
                    "邮储银行",
                    "明星股",
                    "涨超4%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "农业",
                    "生物科技",
                    "化工",
                    "家电",
                    "银行"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "牧原股份、智飞生物、万华化学、海尔智家、邮储银行等明星股涨超4%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医疗健康行业：调整是布局良机 重点新冠疫苗加速接种带来的投资机会",
            "features": {
                "keywords": [
                    "医疗健康",
                    "调整",
                    "布局良机",
                    "新冠疫苗",
                    "接种",
                    "投资机会"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗健康",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医疗健康行业：调整是布局良机 重点新冠疫苗加速接种带来的投资机会",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业报告：创新药企商业化能力的再思考",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新药企",
                    "商业化能力",
                    "再思考"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业报告：创新药企商业化能力的再思考",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：从政府工作报告厘清医药投资逻辑",
            "features": {
                "keywords": [
                    "医药",
                    "政府工作报告",
                    "投资逻辑"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：从政府工作报告厘清医药投资逻辑",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]